Body composition measurement and diabetes - A new perspective on development of antibodies after SARS-CoV-2 booster vaccination.

IF 2.1 Q4 ENDOCRINOLOGY & METABOLISM

Journal of Diabetes and Metabolic Disorders Pub Date : 2025-10-25 eCollection Date: 2025-12-01 DOI:10.1007/s40200-025-01699-1

Lukas Van Baal, Susanne Tan, Dagmar Fuhrer, Johanna Reinold, Ulf Dittmer, Melanie Fiedler

{"title":"Body composition measurement and diabetes - A new perspective on development of antibodies after SARS-CoV-2 booster vaccination.","authors":"Lukas Van Baal, Susanne Tan, Dagmar Fuhrer, Johanna Reinold, Ulf Dittmer, Melanie Fiedler","doi":"10.1007/s40200-025-01699-1","DOIUrl":null,"url":null,"abstract":"Purpose: In patients with SARS-CoV-2 infection overweight and diabetes are associated with poor prognosis. Therefore, effectiveness and tolerance of booster vaccination against SARS-CoV-2 has to be ensured. We examined the impact of overweight and diabetes on anti-SARS-CoV-2-titers and the incidence of side effects after booster vaccination.Methods: We performed a cross-sectional study with consecutive recruitment and convenience sampling of 100 participants vaccinated three times against SARS-CoV-2. Anti-SARS-CoV-2-titers, immunological parameters and biochemical markers of glucose metabolism were measured. Prevalence of vaccination side effects was assessed by personal interview. Moreover, metabolic status was assessed by performance of body composition measurement and body impedance analysis. The glycemic and metabolic parameters were correlated with the anti-SARS-CoV-2-titers and the incidence of side effects. The results were compared between patient with and without overweight and diabetes.Results: Levels of anti-SARS-CoV-2-titers did not differ between participants with and without overweight (5756.6 ± 6848.9 vs. 4997.0 ± 5050.3, p.83) or participants with and without diabetes (6681.0 ± 6795.2 vs. 5124.0 ± 5070.4 BAU/ml, p = .28). Moreover, the investigated glycemic parameters and parameters of the body composition measurement and body impedance analysis did not present any correlation with the antibody levels. Furthermore, we could reveal that vaccination side effects are more likely to occur in participants without diabetes (OR 2.9 (95%-CI: 0.5-4.3, p.04)).Conclusions: Overweight and diabetes are not associated with lower anti-SARS-CoV-2-titers after booster vaccination. Parameters of the body composition and body impedance analysis did not reveal any further association regarding development of anti-SARS-CoV-2-titers. Vaccination side effects are more likely to occur in participants without diabetes.Supplementary information: The online version contains supplementary material available at 10.1007/s40200-025-01699-1.","PeriodicalId":15635,"journal":{"name":"Journal of Diabetes and Metabolic Disorders","volume":"24 2","pages":"250"},"PeriodicalIF":2.1000,"publicationDate":"2025-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12553712/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetes and Metabolic Disorders","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40200-025-01699-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/12/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: In patients with SARS-CoV-2 infection overweight and diabetes are associated with poor prognosis. Therefore, effectiveness and tolerance of booster vaccination against SARS-CoV-2 has to be ensured. We examined the impact of overweight and diabetes on anti-SARS-CoV-2-titers and the incidence of side effects after booster vaccination.

Methods: We performed a cross-sectional study with consecutive recruitment and convenience sampling of 100 participants vaccinated three times against SARS-CoV-2. Anti-SARS-CoV-2-titers, immunological parameters and biochemical markers of glucose metabolism were measured. Prevalence of vaccination side effects was assessed by personal interview. Moreover, metabolic status was assessed by performance of body composition measurement and body impedance analysis. The glycemic and metabolic parameters were correlated with the anti-SARS-CoV-2-titers and the incidence of side effects. The results were compared between patient with and without overweight and diabetes.

Results: Levels of anti-SARS-CoV-2-titers did not differ between participants with and without overweight (5756.6 ± 6848.9 vs. 4997.0 ± 5050.3, p.83) or participants with and without diabetes (6681.0 ± 6795.2 vs. 5124.0 ± 5070.4 BAU/ml, p = .28). Moreover, the investigated glycemic parameters and parameters of the body composition measurement and body impedance analysis did not present any correlation with the antibody levels. Furthermore, we could reveal that vaccination side effects are more likely to occur in participants without diabetes (OR 2.9 (95%-CI: 0.5-4.3, p.04)).

Conclusions: Overweight and diabetes are not associated with lower anti-SARS-CoV-2-titers after booster vaccination. Parameters of the body composition and body impedance analysis did not reveal any further association regarding development of anti-SARS-CoV-2-titers. Vaccination side effects are more likely to occur in participants without diabetes.

Supplementary information: The online version contains supplementary material available at 10.1007/s40200-025-01699-1.

Abstract Image

查看原文本刊更多论文

体成分测量与糖尿病——SARS-CoV-2强化疫苗接种后抗体发展的新视角

目的：SARS-CoV-2感染患者体重过重和糖尿病与预后不良相关。因此，必须确保加强接种SARS-CoV-2疫苗的有效性和耐受性。我们研究了超重和糖尿病对增强疫苗接种后抗sars - cov -2滴度和副作用发生率的影响。方法：我们采用连续招募和方便抽样的横断面研究方法，对100名接种了三次SARS-CoV-2疫苗的参与者进行了抽样。检测抗sars - cov -2滴度、免疫指标及糖代谢生化指标。通过个人访谈评估疫苗副作用的发生率。此外，通过身体成分测量和身体阻抗分析来评估代谢状况。血糖和代谢参数与抗sars - cov -2滴度和不良反应发生率相关。结果比较了超重和非超重的糖尿病患者。结果：抗sars - cov -2滴度水平在超重和非超重参与者（5756.6±6848.9 vs 4997.0±5050.3,p = 83）或患有和非糖尿病参与者（6681.0±6795.2 vs 5124.0±5070.4 BAU/ml, p = 0.28）之间没有差异。此外，所研究的血糖参数和身体成分测量和身体阻抗分析参数与抗体水平没有任何相关性。此外，我们可以揭示，接种疫苗的副作用更可能发生在没有糖尿病的参与者中（OR为2.9 (95%-CI: 0.5-4.3, p.04)）。结论：超重和糖尿病与加强接种后抗sars - cov -2滴度降低无关。身体组成参数和身体阻抗分析未显示与抗sars - cov -2滴度的发展有任何进一步的关联。接种疫苗的副作用更可能发生在没有糖尿病的参与者身上。补充资料：在线版本提供补充资料，网址为10.1007/s40200-025-01699-1。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Diabetes and Metabolic Disorders Medicine-Internal Medicine

CiteScore

4.80

自引率

3.60%

发文量

210

期刊介绍： Journal of Diabetes & Metabolic Disorders is a peer reviewed journal which publishes original clinical and translational articles and reviews in the field of endocrinology and provides a forum of debate of the highest quality on these issues. Topics of interest include, but are not limited to, diabetes, lipid disorders, metabolic disorders, osteoporosis, interdisciplinary practices in endocrinology, cardiovascular and metabolic risk, aging research, obesity, traditional medicine, pychosomatic research, behavioral medicine, ethics and evidence-based practices.As of Jan 2018 the journal is published by Springer as a hybrid journal with no article processing charges. All articles published before 2018 are available free of charge on springerlink.Unofficial 2017 2-year Impact Factor: 1.816.